# OnCo record estramustine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/estramustine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "estramustine" ;
  schema:name "Estramustine"@en ;
  schema:alternateName "Estramustine phosphate"@en, "Emcyt" ;
  schema:description "Estramustine is an oral prostate cancer drug that combines an oestrogen with an alkylating agent, approved in the United States in 1981 for metastatic disease and later combined with taxanes, though its clotting risk has pushed it out of routine use."@en ;
  schema:url <https://onco.cc/drugs/estramustine/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Estramustine> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=estramustine>, <https://en.wikipedia.org/wiki/Estramustine>, <https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201078> ;
  onco:status "established" ;
  onco:tag "gap-fill", "chembl-universe" ;
  onco:modality "Oral oestradiol and nitrogen mustard conjugate" ;
  onco:approval "US 1981: Palliative treatment of metastatic or progressive prostate cancer" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/tubulin/> ;
  onco:drugs <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/nct00055731/>, <https://onco.cc/trials/nct00004054/>, <https://onco.cc/trials/nct00024167/> .